Damien Patel, MD
Critical Care Medicine · Indianapolis, INNPI 1891929634
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,922 of the $3,125 with a category attached, or 61.5%. 15 manufacturers reported payments, led by Intuitive Surgical at 40.8% of the total. Reporting peaked in 2023 at $1,510 and has fallen 64.4% since, to $537 in 2025.
Across 35 payments — averaging $89.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- Pulmonx Corporation$703
- Abiomed$238
- Inari Medical, Inc.$197
- AstraZeneca$141
- Galvanize Therapeutics, Inc$136
- plus $437 from 9 others
Across 2 payments — averaging $29,908 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cumberland Pharmaceuticals, Inc.$60K
What the payments were for
- Travel & lodging$93530%
- Food & beverage$1,92262%
- Education$2689%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $1,273 |
| Pulmonx Corporation | 4 | $703 |
| Abiomed | 2 | $238 |
| Inari Medical, Inc. | 1 | $197 |
| AstraZeneca | 2 | $141 |
| Galvanize Therapeutics, Inc | 1 | $136 |
| Genentech USA, Inc. | 3 | $134 |
| La Jolla Pharmaceutical Company | 1 | $119 |
| Merck | 2 | $43 |
| Vapotherm Inc | 1 | $32 |
| Romark Laboratories, LC | 2 | $32 |
| Novartis | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Sanofi | 1 | $18 |
| Insmed, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,125 in reported general payments places this provider in the 75th percentile of 158 critical care medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 12 | $65,333 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $20,871 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,317 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $1,328 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $1,188 |
| Montelukast Sodium | 13 | $123 |
| Azithromycin | 12 | $44 |
| Prednisone | 18 | $16 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Indianapolis
- Vrushank PatelIndianapolis$142K
- Christopher KnieseIndianapolis$44K
- Stanley NasrawayIndianapolis$34K
- Ryan BoenteIndianapolis$15K
- David RoeIndianapolis$7K
- Mark MastrodicasaIndianapolis$4K
- Bruce AckermanIndianapolis$3K
- Julio NoriegaIndianapolis$3K
- Nestor AnguianoIndianapolis$3K
- Tanya DevnaniIndianapolis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.